Gilead Sciences | GILD - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
AbbVie USD 42.1B 1.19B 2026-03
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
ALKERMES USD 599.5M 56.06M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amgen USD 24.96B 534M 2026-03
Biogen USD 3B 350.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Coherus Biosciences USD 140.39M 231.91M 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Gilead Sciences USD 9.48B 2.34B 2026-03
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Glaxosmithkline GBP 22.43B 6.39B 2026-03
Incyte USD 1.49B 25.52M 2026-03
J&J USD 54.9B 2.82B 2026-06
Merck USD 26.94B 1.38B 2026-03
Moderna USD 2.4B 408M 2026-03
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novartis USD 31.37B 4.1B 2026-03
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 923.6M 44.82M 2026-03
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sanofi EUR 30.01B 1.66B 2026-03
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
United Therapeutics USD 599.1M 38.5M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03